Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · Real-Time Price · USD
8.66
+0.14 (1.58%)
Oct 8, 2024, 3:02 PM EDT - Market open
1.58%
Market Cap 288.29M
Revenue (ttm) n/a
Net Income (ttm) -77.22M
Shares Out 33.06M
EPS (ttm) -3.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 179,057
Open 8.47
Previous Close 8.52
Day's Range 8.46 - 8.96
52-Week Range 8.22 - 22.33
Beta n/a
Analysts Strong Buy
Price Target 22.14 (+153.9%)
Earnings Date Nov 21, 2024

About LXEO

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic car... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2023
Employees 58
Stock Exchange NASDAQ
Ticker Symbol LXEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price forecast is $22.14, which is an increase of 153.90% from the latest price.

Price Target
$22.14
(153.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...

4 weeks ago - GlobeNewsWire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrate...

2 months ago - GlobeNewsWire

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in...

3 months ago - Seeking Alpha

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.

3 months ago - Benzinga

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at  18 months in participants with elevated LVMI at baseline

3 months ago - GlobeNewsWire

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and ...

3 months ago - GlobeNewsWire

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Corn...

5 months ago - GlobeNewsWire

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...

6 months ago - GlobeNewsWire

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...

6 months ago - GlobeNewsWire

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/...

6 months ago - Seeking Alpha

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...

7 months ago - GlobeNewsWire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027

7 months ago - GlobeNewsWire

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor...

7 months ago - GlobeNewsWire

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...

8 months ago - GlobeNewsWire

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic

10 months ago - GlobeNewsWire

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer's disease Received clearance of LX2006 Clinical Trial Application (CTA) in Canada fo...

10 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was...

1 year ago - Seeking Alpha

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, be...

1 year ago - Market Watch

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Lexeo Therapeutics, Inc. has filed to raise $126 million in an IPO, to support developing treatments for cardiovascular and Alzheimer's conditions. The company's lead candidate, LX2006, is in Phase 1/...

1 year ago - Seeking Alpha

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Lexeo Therapeutics, Inc. has filed for a $100 million IPO to develop treatments for cardiovascular and Alzheimer's conditions, although the final figure may differ. The company's lead candidate, LX200...

1 year ago - Seeking Alpha